An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1395-1405

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

By Henry David H.   Gordan Lucio N.   Charu Veena   Wilhelm Francois E.   Williams Denise   Xie John   Woodman Richard C.  

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1403-1413

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 6, 2015-06 ,pp. : 937-945

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

By Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1895-1903

Informa Healthcare

Access to resources Recommend Favorite

An Open-Label, Randomized, Flexible-Dose, Crossover Study to Assess the Comparative Efficacy and Safety of Sildenafil Citrate and Apomorphine Hydrochloride in Men with Erectile Dysfunction

By  

Urologia Internationalis, Vol. 81, Iss. 4, 2008-12 ,pp. : 409-415

Karger

Access to resources Recommend Favorite